U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H24O3
Molecular Weight 300.3928
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TESTOLACTONE

SMILES

C[C@@]12C=CC(=O)C=C2CC[C@]3([H])[C@]1([H])CC[C@@]4(C)[C@@]3([H])CCC(=O)O4

InChI

InChIKey=BPEWUONYVDABNZ-DZBHQSCQSA-N
InChI=1S/C19H24O3/c1-18-9-7-13(20)11-12(18)3-4-14-15(18)8-10-19(2)16(14)5-6-17(21)22-19/h7,9,11,14-16H,3-6,8,10H2,1-2H3/t14-,15+,16+,18+,19+/m1/s1

HIDE SMILES / InChI
Testolactone (Teslac brand name) is an anti-cancer agent, which was used as adjunctive therapy in the palliative treatment of advanced or disseminated breast cancer. The mechanism of testolactone action is reported to be related to the inhibition of aromatase enzymatic activity. Testolactone is no longer available in the USA.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P11511
Gene ID: 1588.0
Gene Symbol: CYP19A1
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
TESLAC

Approved Use

TESLAC (testolactone tablets, USP) is recommended as adjunctive therapy in the palliative treatment of advanced or disseminated breast cancer in postmenopausal women when hormonal therapy is indicated. It may also be used in women who were diagnosed as having had disseminated breast carcinoma when premenopausal, in whom ovarian function has been subsequently terminated.

Launch Date

1.26144E10
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1 μg/mL
500 mg 4 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TESTOLACTONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3.5 μg × h/mL
500 mg 4 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TESTOLACTONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.7 h
500 mg 4 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TESTOLACTONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
A new hypothesis based on suicide substrate inhibitor studies for the mechanism of action of aromatase.
1982 Aug
Evaluation of the male pubertal onset assay to detect testosterone and steroid biosynthesis inhibitors in CD rats.
2001 Apr
Evidence of a treatable endocrinopathy in infertile men.
2001 Mar
Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome.
2002
McCune-Albright syndrome--the German experience.
2002
Feminizing Sertoli cell tumor associated with Peutz-Jeghers syndrome.
2002 Apr
Aromatase inhibitors for male infertility.
2002 Feb
Flutamide decreases cortisol clearance in patients with congenital adrenal hyperplasia.
2002 Jul
[Androgen replacement therapy].
2002 Jun
Cyclic AMP and the reverse transformation reaction.
2002 Jun
Male LH-independent sexual precocity in a 3.5-year-old boy caused by a somatic activating mutation of the LH receptor in a Leydig cell tumor.
2002 Mar
Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone.
2003 Sep
Aromatase inhibitors in precocious puberty: rationale and experience to date.
2004
Sertoli cell tumor causing prepubertal gynecomastia in a boy with peutz-jeghers syndrome: the outcome of 1-year treatment with the aromatase inhibitor testolactone.
2005
Testotoxicosis: current viewpoint.
2005 Dec
Paediatric management of endocrine complications in McCune-Albright syndrome.
2005 Jan
Adult height after ketoconazole treatment in patients with familial male-limited precocious puberty.
2005 Jan
Dominant transmission of prepubertal gynecomastia due to serum estrone excess: hormonal, biochemical, and genetic analysis in a large kindred.
2005 Jan
Fate of novel Quasi reverse steroidal substrates by Aspergillus tamarii KITA: bypass of lactonisation and an exclusive role for the minor hydroxylation pathway.
2005 May 15
Success of testicular sperm extraction [corrected] and intracytoplasmic sperm injection in men with Klinefelter syndrome.
2005 Nov
Structure-activity relationships of new A,D-ring modified steroids as aromatase inhibitors: design, synthesis, and biological activity evaluation.
2005 Oct 6
Heritability of testosterone levels in 12-year-old twins and its relation to pubertal development.
2006 Aug
Tamoxifen improved final height prediction in a girl with McCune-Albright syndrome: patient report and literature review.
2006 Jan
Use of aromatase inhibitors to increase final height.
2006 Jul 25
A boy with McCune-Albright syndrome associated with GH secreting pituitary microadenoma. Clinical findings and response to treatment.
2006 Jul-Sep
[Testotoxicosis].
2006 Jun 28
Synthesis of steroidal lactone by penicillium citreo-viride.
2006 Nov
Nonsurgical treatment of male infertility: specific and empiric therapy.
2007 Sep
Distinct metabolic handling of 3beta-hydroxy-17a-oxa-D-homo-5alpha-androstan-17-one by the filamentous fungus Aspergillus tamarii KITA: Evidence in support of steroid/hydroxylase binding hypothesis.
2007 Sep
Baeyer-Villiger oxidation of DHEA, pregnenolone, and androstenedione by Penicillium lilacinum AM111.
2008 Dec 22
Statistics and the prostate gland.
2008 Jun
Desmoid tumor of the supraclavicular region: a case report.
2009 Jun 22
Enhanced ERbeta immunoexpression and apoptosis in the germ cells of cimetidine-treated rats.
2009 Nov 18
Alternative strategies for the treatment of classical congenital adrenal hyperplasia: pitfalls and promises.
2010
Management of the adult with congenital adrenal hyperplasia.
2010
An Evidence-Based Model of Multidisciplinary Care for Patients and Families Affected by Classical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.
2010
Growth and reproductive outcomes in congenital adrenal hyperplasia.
2010
3β,11α-Dihy-droxy-17a-oxa-d-homoandrost-5-en-17-one.
2010 Jul 14
Patents

Sample Use Guides

The recommended oral dose is 250 mg qid.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
TESTOLACTONE
HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
INN   USAN  
Official Name English
TESTOLACTONE [HSDB]
Common Name English
TESTOLACTONE [VANDF]
Common Name English
NSC-23759
Code English
TEOLIT
Brand Name English
TESTOLACTONE [USAN]
Common Name English
TESTOLACTONE [MI]
Common Name English
TESTOLACTONE CIII
USP-RS  
Common Name English
TESTOLACTONE CIII [USP-RS]
Common Name English
TESTOLACTONE [USP]
Common Name English
TESTOLACTONE [INN]
Common Name English
TESTOLACTONE [WHO-DD]
Common Name English
TESLAC
Brand Name English
TESTOLACTONE [ORANGE BOOK]
Common Name English
TESTOLACTONE [USP-RS]
Common Name English
SQ-9538
Code English
SQ 9538
Code English
Classification Tree Code System Code
NDF-RT N0000175563
Created by admin on Sat Jun 26 15:31:45 UTC 2021 , Edited by admin on Sat Jun 26 15:31:45 UTC 2021
NDF-RT N0000175080
Created by admin on Sat Jun 26 15:31:45 UTC 2021 , Edited by admin on Sat Jun 26 15:31:45 UTC 2021
DEA NO. 4000
Created by admin on Sat Jun 26 15:31:45 UTC 2021 , Edited by admin on Sat Jun 26 15:31:45 UTC 2021
LIVERTOX 943
Created by admin on Sat Jun 26 15:31:45 UTC 2021 , Edited by admin on Sat Jun 26 15:31:45 UTC 2021
NCI_THESAURUS C2017
Created by admin on Sat Jun 26 15:31:45 UTC 2021 , Edited by admin on Sat Jun 26 15:31:45 UTC 2021
Code System Code Type Description
EVMPD
SUB10936MIG
Created by admin on Sat Jun 26 15:31:45 UTC 2021 , Edited by admin on Sat Jun 26 15:31:45 UTC 2021
PRIMARY
NCI_THESAURUS
C2301
Created by admin on Sat Jun 26 15:31:45 UTC 2021 , Edited by admin on Sat Jun 26 15:31:45 UTC 2021
PRIMARY
FDA UNII
6J9BLA949Q
Created by admin on Sat Jun 26 15:31:45 UTC 2021 , Edited by admin on Sat Jun 26 15:31:45 UTC 2021
PRIMARY
USP_CATALOG
1645006
Created by admin on Sat Jun 26 15:31:45 UTC 2021 , Edited by admin on Sat Jun 26 15:31:45 UTC 2021
PRIMARY USP-RS
DRUG CENTRAL
2606
Created by admin on Sat Jun 26 15:31:45 UTC 2021 , Edited by admin on Sat Jun 26 15:31:45 UTC 2021
PRIMARY
ChEMBL
CHEMBL1571
Created by admin on Sat Jun 26 15:31:45 UTC 2021 , Edited by admin on Sat Jun 26 15:31:45 UTC 2021
PRIMARY
CAS
968-93-4
Created by admin on Sat Jun 26 15:31:45 UTC 2021 , Edited by admin on Sat Jun 26 15:31:45 UTC 2021
PRIMARY
WIKIPEDIA
TESTOLACTONE
Created by admin on Sat Jun 26 15:31:45 UTC 2021 , Edited by admin on Sat Jun 26 15:31:45 UTC 2021
PRIMARY
DRUG BANK
DB00894
Created by admin on Sat Jun 26 15:31:45 UTC 2021 , Edited by admin on Sat Jun 26 15:31:45 UTC 2021
PRIMARY
INN
1839
Created by admin on Sat Jun 26 15:31:45 UTC 2021 , Edited by admin on Sat Jun 26 15:31:45 UTC 2021
PRIMARY
IUPHAR
7303
Created by admin on Sat Jun 26 15:31:45 UTC 2021 , Edited by admin on Sat Jun 26 15:31:45 UTC 2021
PRIMARY
PUBCHEM
13769
Created by admin on Sat Jun 26 15:31:45 UTC 2021 , Edited by admin on Sat Jun 26 15:31:45 UTC 2021
PRIMARY
MERCK INDEX
M10593
Created by admin on Sat Jun 26 15:31:45 UTC 2021 , Edited by admin on Sat Jun 26 15:31:45 UTC 2021
PRIMARY Merck Index
HSDB
3255
Created by admin on Sat Jun 26 15:31:45 UTC 2021 , Edited by admin on Sat Jun 26 15:31:45 UTC 2021
PRIMARY
EPA CompTox
968-93-4
Created by admin on Sat Jun 26 15:31:45 UTC 2021 , Edited by admin on Sat Jun 26 15:31:45 UTC 2021
PRIMARY
ECHA (EC/EINECS)
213-534-6
Created by admin on Sat Jun 26 15:31:45 UTC 2021 , Edited by admin on Sat Jun 26 15:31:45 UTC 2021
PRIMARY
RXCUI
10378
Created by admin on Sat Jun 26 15:31:45 UTC 2021 , Edited by admin on Sat Jun 26 15:31:45 UTC 2021
PRIMARY RxNorm